FOR IMMEDIATE RELEASE
Orthomolecular Medicine News Service, October 17, 2025

Cancer Care Reimagined: 25th Annual Riordan Clinic Conference Brings Orthomolecular Pioneers Together

by Richard Z. Cheng, M.D., Ph.D., Editor-in-Chief, OMNS

• 🎗 Cancer Care Reimagined - 25th Annual Riordan Clinic Conference
• 🔬 40+ years of high-dose IV vitamin C (HDIVC) research
• 🌍 Global experts in orthomolecular and metabolic oncology
• 🧬 Topics: Mitochondria, metabolism, toxins, and root-cause cancer care
• 🎤 Featured speakers include Dr. Ron Hunninghake, Dr. Thomas Levy, Dr. Ilyes Baghli, Dr. Paul Anderson, and other leaders in orthomolecular and metabolic oncology - including presentations on mitochondria, metabolism, and root-cause cancer care.
• 💡 OMNS members receive $50 off registration with code "OMNS."

A Historic Gathering in Wichita

The Riordan Clinic's 25th Annual Conference marks half a century of advancing nutritional and metabolic medicine. This year's theme, Cancer Care Reimagined, brings together leading clinicians, scientists, and advocates to discuss integrative, orthomolecular, and metabolic approaches to cancer.

📌 Riordan Clinic: 40+ Years of HDIVC Research

• 1970s - Linus Pauling & Ewan Cameron published the first clinical reports on vitamin C and cancer, sparking worldwide interest [1].
• 1975 - In Wichita, Dr. Hugh Riordan began intravenous vitamin C research, moving beyond oral dosing and developing systematic clinical use in cancer patients.
• Late 1970s-1980s - Dr. Riordan and colleagues began systematic clinical use of high-dose intravenous vitamin C (HDIVC) for cancer patients, inspired by Linus Pauling and Ewan Cameron's pioneering work.
• 1990s - The Riordan team published groundbreaking pharmacokinetic studies demonstrating that IV vitamin C achieves plasma concentrations 100-200 times higher than oral dosing-levels capable of exerting pharmacologic, anti-cancer effects [2].
• 2000s - Under Dr. Ron Hunninghake's leadership, Riordan Clinic expanded HDIVC protocols, published clinical outcomes, and trained physicians worldwide.
• 2010s-2020s - The Clinic contributed to global collaborative trials, broadened the evidence base for HDIVC in cancer, sepsis, and infections, and became an international referral center for orthomolecular oncology.

👉 Today: With more than 40 years of uninterrupted HDIVC research and clinical practice, the Riordan Clinic stands as the world's leading institution in advancing vitamin C therapy for cancer and chronic disease.

Dr. Riordan's Legacy and the HDIVC Movement

Dr. Hugh Riordan (1932-2005) dedicated his career to exploring safe, non-toxic, nutritional approaches to cancer. Long before mainstream medicine took interest, he and his colleagues published groundbreaking research demonstrating that vitamin C-when administered intravenously at pharmacologic doses-could selectively kill cancer cells, improve quality of life, and enhance treatment tolerance.

Since then, Dr. Hunninghake, Dr. Thomas Levy, and many others have carried forward this mission. Together, they have expanded clinical protocols, generated clinical trial data, and trained physicians globally in orthomolecular approaches to cancer therapy.

Orthomolecular Medicine: A Global Vision

Orthomolecular medicine is rooted in optimal nutrition and biochemical balance, addressing not only cancer but also cardiovascular disease, infections, autoimmune disorders, and the chronic disease epidemic of our time.

The presence of Dr. Ilyes Baghli, current President of the International Society for Orthomolecular Medicine (ISOM), highlights the global unification of orthomolecular medicine. His keynote will emphasize the shared mission of advancing safe, science-based nutritional medicine across continents.

Why "Cancer Care Reimagined"?

Conventional oncology remains overwhelmingly mutation- and drug-centric, often overlooking root causes such as:

• Mitochondrial dysfunction
• Nutritional deficiencies
• Oxidative stress and toxin overload
• Immune imbalance

This conference reframes cancer care by integrating safe, effective, and affordable approaches that empower both patients and providers. It will present not only the science of HDIVC, but also innovations in metabolic therapy, lifestyle interventions, and orthomolecular nutrition.

Highlights of the 2025 Conference

• Celebrating 50 years of the Riordan Clinic's leadership in integrative medicine.
• 40+ years of clinical and research experience with HDIVC.
• A leading team of integrative oncology and functional medicine experts, convened by Dr. Ron Hunninghake.
• Full panel of speakers and topics:
  • Dr. Ron Hunninghake: The Third Medical Revolution: Reuniting the Divided Brain
  • Manickam Mahalingam & Dr. Pradeep MK Nair: Hallmark of Cancers: The Genetic-Metabolic Crosstalk
  • Dr. Thomas Levy: Vitamin C and Cortisol: Synergistic Immune Partners
  • Ivelisse Paige: TBD
  • Dr. Ilyes Baghli: Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment
  • Shaun Noorian: Advancing Integrative Oncology: The Role of Compounded Therapies in Supportive Cancer Care
  • Dr. Richard Cheng: From Mutations to Metabolism: Toxins and Mitochondria as the Central Axis of Cancer, ASCVD, and T2DM
  • Dr. Lise Alschuler: Fungi: Healing Synergism
  • Dr. Paul Anderson: Oncology Treatment Targets and Stratification
  • Dr. Dan Rubin: TBD
  • Dr. Nasha Winters: What's Working: Reimagining Cancer Care Through the Terrain Lens
  • Robin Daly: TBD
  • Mark Lintern: A New Perspective on the Origin of Cancer: Exploring a Suppression-based Model
  • Neil Riordan: TBD
• International panel of experts including orthomolecular physicians, researchers, and patient advocates.
• Hybrid format: live in Wichita and broadcast worldwide.
• Practical tools for clinicians and patients applying integrative strategies safely and effectively.

A Movement for the Future

By partnering with the Riordan Clinic, your brand won't just be seen-you'll be aligned with a movement. A movement that empowers clinicians, inspires patients, and accelerates the future of cancer care.

The collective audience reach spans 200,000+ monthly social media impressions, 90,000+ monthly podcast downloads, and 28,500 newsletter subscribers, ensuring that the insights shared in Wichita extend far beyond the two days in November. Cancer Care Reimagined carries the Riordan Clinic's 50-year legacy forward, bringing together global experts, innovative science, and a deeply engaged audience of providers ready to translate evidence into action.

A Call to Action

As cancer continues to affect millions worldwide, the need for safe, affordable, and effective approaches has never been greater. The Riordan Clinic has carried this torch for half a century, and the 25th Annual Cancer Care Reimagined Conference is both a celebration of this legacy and a call to the future.

Orthomolecular medicine stands at the intersection of science, safety, and accessibility. From the pioneering vision of Dr. Hugh Riordan to today's growing community of practitioners and patients, the message remains clear: nutritional medicine saves lives.

Learn More & Share

👉 Conference hub (share this page): https://www.cancercarereimagined.org/

👉 General info & registration: https://www.cancercarereimagined.org/register

💡 OMNS community members receive a $50 registration discount when signing up for this historic event using the code OMNS.

References

1. Cameron E, Pauling L. The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. Chem Biol Interact. 1974 Oct;9(4):273-83. doi: 10.1016/0009-2797(74)90018-0 PMID: 4609626.

2. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976 Oct;73(10):3685-9. doi: 10.1073/pnas.73.10.3685 PMID: 1068480; PMCID: PMC431183.

3. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses. 1995 Mar;44(3):207-13. doi: 10.1016/0306-9877(95)90137-x. PMID: 7609676.

4. Jackson JA, Riordan HD, Schultz M. Case Study: High-Dose Intravenous Vitamin C in the Treatment of a Patient with Adenocarcinoma of the Kidney. Journal of Orthomolecular Medicine. 1990;5(1):5-7. https://orthomolecular.org/library/jom/1990/pdf/1990-v05n01-p005.pdf or https://isom.ca/wp-content/uploads/2020/01/JOM_1990_05_1_02_Case_study_High_Dose_intravenous_Vitamin_C_in_the-.pdf

5. Riordan N, Jackson JA, Riordan HD. Intravenous vitamin C in a terminal cancer patient. J Orthomol Med. 1996;11(2):80-82. https://orthomolecular.org/library/jom/1996/pdf/1996-v11n02-p080.pdf or https://isom.ca/wp-content/uploads/2020/01/JOM_1996_11_2_04_Intravenous_Vitamin_C_in_A_Terminal_Cancer_Patient.pdf

About the Author

Richard Z. Cheng, M.D., Ph.D. - Editor-in-Chief, Orthomolecular Medicine News Service (orthomolecular.org)

Dr. Cheng is a U.S.-based, NIH-trained, board-certified physician specializing in integrative cancer therapy, orthomolecular medicine, functional & anti-aging medicine. He maintains active practices in both the United States and China.

A Fellow of the American Academy of Anti-Aging Medicine and a Hall of Fame inductee of the International Society for Orthomolecular Medicine, Dr. Cheng is a leading advocate for nutrition-based, root-cause health strategies. He also serves as an expert reviewer for the South Carolina Board of Medical Examiners, and co-founded both the China Low Carb Medicine Alliance and the Society of International Metabolic Oncology.

Dr. Cheng offers online Integrative Orthomolecular Medicine consultation services.
📰 Follow his latest insights on Substack: https://substack.com/@rzchengmd

Orthomolecular Medicine

Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org

Find a Doctor

To locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

Editorial Review Board:

Jennifer L. Aliano, M.S., L.Ac., C.C.N. (USA)
Albert G. B. Amoa, MB.Ch.B, Ph.D. (Ghana)
Seth Ayettey, M.B., Ch.B., Ph.D. (Ghana)
Ilyès Baghli, M.D. (Algeria)
Greg Beattie, Author (Australia)
Barry Breger, M.D. (Canada)
Ian Brighthope, MBBS, FACNEM (Australia)
Gilbert Henri Crussol, D.M.D. (Spain)
Carolyn Dean, M.D., N.D. (USA)
Ian Dettman, Ph.D. (Australia)
Susan R. Downs, M.D., M.P.H. (USA)
Ron Ehrlich, B.D.S. (Australia)
Hugo Galindo, M.D. (Colombia)
Gary S. Goldman, Ph.D. (USA)
William B. Grant, Ph.D. (USA)
Claus Hancke, MD, FACAM (Denmark)
Patrick Holford, BSc (United Kingdom)
Ron Hunninghake, M.D. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Dwight Kalita, Ph.D. (USA)
Felix I. D. Konotey-Ahulu, M.D., FRCP (Ghana)
Peter H. Lauda, M.D. (Austria)
Fabrice Leu, N.D., (Switzerland)
Alan Lien, Ph.D. (Taiwan)
Homer Lim, M.D. (Philippines)
Stuart Lindsey, Pharm.D. (USA)
Pedro Gonzalez Lombana, M.D., Ph.D. (Colombia)
Diana MacKay (Gifford-Jones), M.P.P. (Canada)
Victor A. Marcial-Vega, M.D. (Puerto Rico)
Juan Manuel Martinez, M.D. (Colombia)
Mignonne Mary, M.D. (USA)
Dr.Aarti Midha M.D., ABAARM (India)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Sarah Myhill, MB, BS (United Kingdom)
Tahar Naili, M.D. (Algeria)
Zhiwei Ning, M.D., Ph.D. (China)
Zhiyong Peng, M.D. (China)
Pawel Pludowski, M.D. (Poland)
Isabella Akyinbah Quakyi, Ph.D. (Ghana)
Selvam Rengasamy, MBBS, FRCOG (Malaysia)
Jeffrey A. Ruterbusch, D.O. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
Thomas N. Seyfried, Ph.D. (USA)
Han Ping Shi, M.D., Ph.D. (China)
T.E. Gabriel Stewart, M.B.B.CH. (Ireland)
Jagan Nathan Vamanan, M.D. (India)
Dr. Sunil Wimalawansa, M.D., Ph.D. (Sri Lanka)

Andrew W. Saul, Ph.D. (USA), Founding & Former Editor
Richard Cheng, M.D., Ph.D. (USA), Editor-In-Chief
Associate Editor: Robert G. Smith, Ph.D. (USA)
Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)
Editor, Chinese Edition: Richard Cheng, M.D., Ph.D. (USA)
Editor, Norwegian Edition: Dag Viljen Poleszynski, Ph.D. (Norway)
Editor, Arabic Edition: Moustafa Kamel, R.Ph, P.G.C.M (Egypt)
Editor, Korean Edition: Hyoungjoo Shin, M.D. (South Korea)
Editor, Spanish Edition: Sonia Rita Rial, PhD (Argentina)
Editor, German Edition: Bernhard Welker, M.D. (Germany)
Associate Editor, Arabic Edition: Ayman Kamel, DVM, MBA (Egypt)
Associate Editor, German Edition: Gerhard Dachtler, M.Eng. (Germany)
Assistant Editor: Michael Passwater (USA)
Contributing Editor: Thomas E. Levy, M.D., J.D. (USA)
Contributing Editor: Damien Downing, M.B.B.S., M.R.S.B. (United Kingdom)
Contributing Editor: W. Todd Penberthy, Ph.D. (USA)
Contributing Editor: Michael J. Gonzalez, N.M.D., Ph.D. (Puerto Rico)
Technology Editor: Michael S. Stewart, B.Sc.C.S. (USA)
Associate Technology Editor: Robert C. Kennedy, M.S. (USA)
Legal Consultant: Jason M. Saul, JD (USA)

Comments and media contact: editor@orthomolecular.org OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication.

To Subscribe at no charge: http://www.orthomolecular.org/subscribe.html

To Unsubscribe from this list: http://www.orthomolecular.org/unsubscribe.html